Symbiotec Pharmalab IPO Details
| IPO Open Date | 2026 |
| IPO Close Date | 2026 |
| Face Value | ā¹2 Per Equity Share |
| IPO Price Band | ā¹[.] to ā¹[.] Per Share |
| Issue Size | Approx ā¹2,180 Crores |
| Fresh Issue | Approx ā¹150 Crores |
| Offer for Sale: | Approx [.] Equity Shares |
| Issue Type | Book Building Issue |
| IPO Listing | BSE, NSE |
| DRHP Draft Prospectus |  |
| RHP Draft Prospectus | |
Symbiotec Pharmalab IPO Review & Key Points
- Review:
Symbiotec Pharmalab IPO Market Lot
The Symbiotec Pharmalab IPO minimum market lot is [.] shares with ā¹[.] application amount. The retail investors can apply up-to 13 lots with [.] shares of ā¹[.] amount.
| Application | Lot Size | Shares | Amount |
| Retail Minimum | – | – | ā¹- |
| Retail Maximum | – | – | ā¹- |
| S-HNI Minimum | – | – | ā¹- |
| S-HNI Maximum | – | – | ā¹- |
| B-HNI Minimum | – | – | ā¹- |
IPO Reservation
| Investor Category | Share Offered | -% Shares |
| Anchor Investor | – Shares | -% |
| QIB (Ex. Anchor) | – Shares | 50% |
| NII Shares Offered | – Shares | 15% |
| Retail Shares Offered | – Shares | 35% |
Symbiotec Pharmalab IPO Anchor Investors
| Anchor Bidding Date | 2026 |
| Anchor Investors List | |
| Shares Offered | [.] Shares |
| Anchor Size | [.] Cr. |
| lock-in period end date 50% shares (30 Days) | 2026 |
| lock-in period end date 50% shares (90 Days) | 2026 |
Symbiotec Pharmalab IPO Dates
The Symbiotec Pharmalab IPO date is 2026, and the close date is 2026. The Symbiotec Pharmalab IPO allotment will be finalized in 2026, and the IPO listing on 2026.
| IPO Open Date: | 2026 |
| IPO Close Date: | 2026 |
| Basis of Allotment: | 2026 |
| Refunds: | 2026 |
| Credit to Demat Account: | 2026 |
| IPO Listing Date: | 2026 |
| IPO Bidding Cut-off Time: | January 2026 – 5 PM |
Promoters and Holding Pattern
The promoters of the company are Anil Satwani, Kashish Satwani, Sushil Satwani and Satwani Holdings LLP.
| Particular | Shares | % Share |
| Promoter Holding Pre Issue | 6,16,81,496 | 34.47% |
| Promoter Holding Post Issue | – | -% |
Objects of the Issue & Utilisation of proceeds
| Purpose | Crores |
| Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the Company | ā¹112.50 |
| General Corporate Purpose | ā¹- |
About Symbiotec Pharmalab IPO
To be updated soon
Symbiotec Pharmalab IPO Company Financial Report
Amount ā¹ in Crores
| Period Ended | Revenue | Expense | PAT | Assets |
| 2023 | ā¹572.97 | ā¹533.63 | ā¹23.49 | ā¹989.99 |
| 2024 | ā¹723.33 | ā¹590.99 | ā¹100.06 | ā¹1,294.79 |
| 2025 | ā¹755.98 | ā¹608.85 | ā¹96.79 | ā¹1,579.65 |
| Jun 2025 | ā¹205.81 | ā¹160.99 | ā¹29.92 | ā¹1,598.34 |
Symbiotec Pharmalab IPO Valuation – FY2025
Check Symbiotec Pharmalab IPO valuations detail like Earning Per Share (EPS), Price/Earning P/E Ratio, Return on Net Worth (RoNW), and Net Asset Value (NAV) details.
| KPI | Values |
| ROE: | 12.66% |
| ROCE: | 11.80% |
| EBITDA Margin: | 29.45% |
| PAT Margin: | 12.80% |
| Debt to equity ratio: | – |
| Earning Per Share (EPS): | ā¹17.70(Basic) |
| Price/Earning P/E Ratio: | N/A |
| Return on Net Worth (RoNW): | 11.79% |
| Net Asset Value (NAV): | ā¹150.17 |
Peer Group Comparison
| Company | EPS | PE Ratio | RoNW % | NAV | Income |
| Concord Biotech Limited | 35.52 | 38.59 | 22.00 | N.A. | 1200.09 Cr. |
| Divi’s Laboratories Limited | 82.53 | 77.87 | 14.83 | 562.00 | 9360.00 Cr. |
| Cohance Lifesciences Limited | 12.79 | 42.31 | 19.10 | N.A | 2608.50 Cr. |
| Laurus Labs Limited | 6.65 | 152.85 | 8.00 | 82.95 | 5554.00 Cr. |
IPO Lead Managers aka Merchant Bankers
- JM Financial Ltd.
- Avendus Capital Pvt.Ltd.
- Motilal Oswal Investment Advisors Ltd.
- Nomura Financial Advisory & Securities (India) Pvt.Ltd.
Company Address
Symbiotec Pharmalab Ltd.
385/2,
Pigdamber, Rau,
Mhow,
Indore, Madhya Pradesh, 453331
Phone: +91 731 667 6405
Email: secretarial@symbiotec.com
Website: http://www.symbiotec.com/
IPO Registrar
MUFG Intime India Pvt.Ltd.
Phone: +91-22-4918 6270
Email: symbiotecpharmalab.ipo@in.mpms.mufg.com
Website: https://in.mpms.mufg.com/Initial_Offer/public-issues.html
Symbiotec Pharmalab IPO FAQs
What is Symbiotec Pharmalab IPO?
Symbiotec Pharmalab IPO is Mainboard IPO. The company is going to raise ā¹[.] Crores via IPO. The issue is priced at ā¹[.] to ā¹[.] per equity share. The IPO is to be listed on BSE & NSE.
When Symbiotec Pharmalab IPO will open for subscription?
The IPO is to open on 2026 for QIB, NII, and Retail Investors. The IPO will close on 2026.
What is Symbiotec Pharmalab IPO Investors Portion?
The investors’ portion for QIB is 50%, NII is 15%, and Retail is 35%.
How to Apply the Symbiotec Pharmalab IPO?
You can apply for Symbiotec Pharmalab IPO via ASBA online via your bank account. You can also apply for ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form.
What is Symbiotec Pharmalab IPO Issue Size?
Symbiotec Pharmalab IPO issue size is ā¹2,180 crores.
What is Symbiotec Pharmalab IPO Price Band?
Symbiotec Pharmalab IPO Price Band is ā¹[.] to ā¹[.].
What is Symbiotec Pharmalab IPO Lot Size?
The minimum bid is [.] Shares with ā¹[.] amount.
What is the Symbiotec Pharmalab IPO Allotment Date?
Symbiotec Pharmalab IPO allotment date is 2026.
What is the Symbiotec Pharmalab IPO Listing Date?
Symbiotec Pharmalab IPO listing date is 2026. The IPO is to list on BSE & NSE.
Note: The Symbiotec Pharmalab IPO price band and date are officially announced. The (Symbiotec Pharmalab IPO grey market premium) will be added to the IPO GMP page as it will start).
